Not yet recruitingPhase 2NCT05970627
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Studying Epstein-Barr virus-associated gastric carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yu jiren
- Principal Investigator
- Jiren YuFirst Affiliated Hospital of Zhejiang University
- Intervention
- Toripalimab(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2029
Study locations (8)
- The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- Huzhou Central Hospital, Huzhou, Zhejiang, China
- Lishui Central Hospital, Lishui, Zhejiang, China
- Ningbo First Hospital, Ningbo, Zhejiang, China
- Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
- Ningbo Second Hospital, Ningbo, Zhejiang, China
- Taizhou Hospital, Taizhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05970627 on ClinicalTrials.gov